Pirtenidine

Pirtenidine

SCHEMBL2108103

CCCCCCCCN=c1ccn(CCCCCCCC)cc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.56
RAB9A P51151 7/20 0.56
HTT P42858 6/20 0.56
MAPK1 P28482 4/20 0.56
LMNA P02545 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HSP90AA1 P07900 3/20 0.56
GALR3 O60755 2/20 0.56
POLB P06746 2/20 0.56
ATM Q13315 2/20 0.56
APOBEC3A P31941 2/20 0.56
APOBEC3G Q9HC16 2/20 0.56
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
RAD52 P43351 1/20 0.56
PAX8 Q06710 1/20 0.56
NR2F2 P24468 1/20 0.56
NOD2 Q9HC29 1/20 0.56
ALDH1A1 P00352 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23393769 1.00 NPC1 (0.56) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL124821 1.00 NPC1 (0.56) NPC1RAB9AHTTMAPK1LMNA
SCHEMBL10570053 1.00 NPC1 (0.56) NPC1RAB9AHTTMAPK1LMNA
SCHEMBL10569601 1.00 NPC1 (0.56) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL20764598 1.00 NPC1 (0.56) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL2594550 0.98 NPC1 (0.54) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL16836483 0.98 NPC1 (0.54) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL986183 0.98 NPC1 (0.54) NPC1RAB9AHTTMAPK1LMNA
Octenidine SCHEMBL20597431 0.98 NPC1 (0.59) NPC1RAB9AHTTMAPK1LMNA
Hydrochloric Acid SCHEMBL10573221 0.98 NPC1 (0.54) NPC1RAB9AHTTMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3969486-A1 ELASTOMERIC SILICONE COMPOSITIONS COMPRISING GLYCEROL, CYCLODEXTRIN AND OCTENIDINE Coloplast A/S (DK) 2022-03-23 EP claimed
WO-2020228917-A1 ELASTOMERIC SILICONE COMPOSITIONS COMPRISING GLYCEROL, CYCLODEXTRIN AND OCTENIDINE COLOPLAST A/S (DK) 2020-11-19 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-0174632-B1 ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF STERLING DRUG INC. (US) 1990-02-07 EP claimed
US-4598082-A DENTISTRY STERLING DRUG INC. (US) 1986-07-01 US claimed
EP-0174632-A1 Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof STERLING DRUG INC. (US) 1986-03-19 EP claimed
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF Bio Logic Crop Science S.L. (ES) 2025-01-16 US disclosed
EP-4427745-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF Bio Logic Crop Science, S.L. (ES) 2024-09-11 EP disclosed
US-11766364-B2 Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents ETHICON, INC. (US) 2023-09-26 US disclosed
EP-3969486-B1 ELASTOMERIC SILICONE COMPOSITIONS COMPRISING GLYCEROL, CYCLODEXTRIN AND OCTENIDINE COLOPLAST AS (DK) 2023-07-12 EP disclosed
CN-113795518-B Elastomeric silicone composition comprising glycerin, cyclodextrin and octenidine 科洛普拉斯特公司 2023-06-09 CN disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
EP-0174632-B1 ANTI-MICROBIAL N-(1-(ALKYL OR ARYLMETHYL)-4(1H)-PYRIDINYLIDINE)ALKANAMINES AND ACID ADDITION SALTS THEREOF AND PROCESS FOR PREPARATION, METHODS OF USE AND COMPOSITIONS THEREOF STERLING DRUG INC. (US) 1990-02-07 EP disclosed
US-4839372-A ANTIPLAQUE AGENTS STERLING DRUG INC. (US) 1989-06-13 US disclosed
US-4598082-A DENTISTRY STERLING DRUG INC. (US) 1986-07-01 US disclosed
EP-0174632-A1 Anti-microbial N-(1-(alkyl or arylmethyl)-4(1H)-pyridinylidine)alkanamines and acid addition salts thereof and process for preparation, methods of use and compositions thereof STERLING DRUG INC. (US) 1986-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017879-A1 COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF SARS1, ACE2, PHOSPHO1 NPC1 2226/4885RAB9A 2437/4885HTT 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.